Company Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders.
In addition, the company’s preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson’s Disease; NMRA-CK1δ, a casein kinase 1 isoform delta (CK1δ) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Henry Gosebruch |
Contact Details
Address: 260 Arsenal Place, Suite 1 Watertown, Massachusetts 02472 United States | |
| Phone | 857 760 0900 |
| Website | neumoratx.com |
Stock Details
| Ticker Symbol | NMRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1885522 |
| CUSIP Number | 640979100 |
| ISIN Number | US6409791000 |
| Employer ID | 84-4367680 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joshua Pinto Ph.D. | President |
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg and Development officer |
| Carol Suh | Co-Founder and Chief Strategy Officer |
| Michael Lee Milligan | Chief Financial Officer and Principal Accounting Officer |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer |
| Pablo Gersberg | Chief Information Officer |
| Jason G. Duncan J.D. | Chief Legal and Administrative Officer |
| Helen Rubinstein | Head of Investor Relations |
| Amy Sullivan | Chief Human Resources Officer |
| Lori Houle | Chief Technical Operations and Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 4, 2026 | SCHEDULE 13G/A | Filing |
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2026 | SCHEDULE 13D/A | Filing |
| Mar 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 30, 2026 | 8-K | Current Report |